SCHEMBL1581979

SCHEMBL1581979

CNS(=O)(=O)c1ccc(C2(C(=O)Nc3nccs3)CC2C2CCCCC2)cc1C(F)(F)F

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GCK P35557 7/20 0.64
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
KCNH2 Q12809 1/20 0.39
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
LMNA P02545 3/20 0.38
TSHR P16473 2/20 0.38
MAPT P10636 2/20 0.38
HTT P42858 2/20 0.38
USP2 O75604 2/20 0.38
POLB P06746 1/20 0.38
STAT3 P40763 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPK1 P28482 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
EPHX2 P34913 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2666311 1.00 GCK (0.64) GCKMEN1KMT2AKCNH2ALDH1A1
SCHEMBL12720791 0.92 GCK (0.71) GCKMEN1KMT2AKCNH2ALDH1A1
SCHEMBL1582471 0.92 GCK (0.71) GCKMEN1KMT2AKCNH2ALDH1A1
SCHEMBL13757082 0.87 GCK (0.47) GCKKMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL1582126 0.87 GCK (0.47) GCKKMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL2666188 0.84 GCK (0.82) GCKMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL1582183 0.84 GCK (0.82) GCKMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL1581651 0.82 GCK (0.74) GCKMEN1KMT2AKCNH2SMN1; SMN2
SCHEMBL13757059 0.82 GCK (0.74) GCKMEN1KMT2AKCNH2SMN1; SMN2
SCHEMBL2656522 0.82 CNR2 (0.39) GCKEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576108-B2 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY (US) 2009-08-18 US claimed
EP-1585739-B1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS LILLY CO ELI (US) 2011-04-20 EP disclosed
US-7576108-B2 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY 2006-05-25 US disclosed
EP-1585739-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2005-10-19 EP disclosed
WO-2004063179-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators GCK, GCKR, GALK1 GCK 1/4885MEN1 4564/4885KMT2A 1603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.